Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Summit Therapeutics ( (SMMT) ).
On January 22, 2025, Summit Therapeutics’ Board approved cash bonus awards for Dr. Mahkam Zanganeh, CEO, and Manmeet Soni, CFO, for their performance in the 2024 fiscal year, despite no bonuses being issued in 2023. The Board also increased their annual base salaries starting February 1, 2025. As of December 31, 2024, the company’s preliminary unaudited cash and investment balance was approximately $412 million, including the repayment of a $31.8 million related party loan, indicating a robust financial position.
More about Summit Therapeutics
Summit Therapeutics Inc. operates in the healthcare industry, focusing on developing and commercializing pharmaceutical products.
YTD Price Performance: 34.33%
Average Trading Volume: 2,244,012
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $18.18B
See more insights into SMMT stock on TipRanks’ Stock Analysis page.
